New Data for Sacituzumab Govitecan-hziy in the Treatment of Metastatic Triple-Negative Breast Cancer

被引：0
|
作者：
Bardia, Aditya [1 ,2 ]
机构：
[1] Breast Canc Res Program, Boston, MA 02115 USA
[2] Harvard Med Sch, Med Oncol, Massachusetts Gen Hosp, Boston, MA 02115 USA
来源：
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY | 2021年 / 19卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：723 / 725
页数：3
相关论文
共 50 条
  • [1] Sacituzumab govitecan-hziy for triple-negative breast cancer
    Stirrups, Robert
    LANCET ONCOLOGY, 2019, 20 (04): : E194 - E194
  • [2] Sacituzumab Govitecan-hziy in Triple-Negative Breast Cancer
    Ozaki, Yukinori
    Masuda, Jun
    Takano, Toshimi
    NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (24): : 2382 - 2382
  • [3] Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer
    Bardia, A.
    Mayer, I. A.
    Vahdat, L. T.
    Tolaney, S. M.
    Isakoff, S. J.
    Diamond, J. R.
    O'Shaughnessy, J.
    Moroose, R. L.
    Santin, A. D.
    Abramson, V. G.
    Shah, N. C.
    Rugo, H. S.
    Goldenberg, D. M.
    Sweidan, A. M.
    Iannone, R.
    Washkowitz, S.
    Sharkey, R. M.
    Wegener, W. A.
    Kalinsky, K.
    NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (08): : 741 - 751
  • [4] Sacituzumab Govitecan-hziy: An Antibody-Drug Conjugate for the Treatment of Refractory, Metastatic, Triple-Negative Breast Cancer
    Seligson, John M.
    Patron, Alexandra M.
    Berger, Michael J.
    Harvey, R. Donald
    Seligson, Nathan D.
    ANNALS OF PHARMACOTHERAPY, 2021, 55 (07) : 921 - 931
  • [5] Sacituzumab Govitecan-hziy in Breast Cancer
    Kwapisz, Dorota
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2022, 45 (07): : 279 - 285
  • [6] FDA Approval Summary: Accelerated Approval of Sacituzumab Govitecan-hziy for Third-line Treatment of Metastatic Triple-negative Breast Cancer
    Wahby, Sakar
    Fashoyin-Aje, Lola
    Osgood, Christy L.
    Cheng, Joyce
    Fiero, Mallorie H.
    Zhang, Lijun
    Tang, Shenghui
    Hamed, Salaheldin S.
    Song, Pengfei
    Charlab, Rosane
    Dorff, Sarah E.
    Ricks, Tiffany K.
    Barnett-Ringgold, Kimberly
    Dinin, Jeannette
    Goldberg, Kirsten B.
    Theoret, Marc R.
    Pazdur, Richard
    Amiri-Kordestani, Laleh
    Beaver, Julia A.
    CLINICAL CANCER RESEARCH, 2021, 27 (07) : 1850 - 1854
  • [7] Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer
    Bardia, A.
    Hurvitz, S. A.
    Tolaney, S. M.
    Loirat, D.
    Punie, K.
    Oliveira, M.
    Brufsky, A.
    Sardesai, S. D.
    Kalinsky, K.
    Zelnak, A. B.
    Weaver, R.
    Traina, T.
    Dalenc, F.
    Aftimos, P.
    Lynce, F.
    Diab, S.
    Cortes, J.
    O'Shaughnessy, J.
    Dieras, V
    Ferrario, C.
    Schmid, P.
    Carey, L. A.
    Gianni, L.
    Piccart, M. J.
    Loibl, S.
    Goldenberg, D. M.
    Hong, Q.
    Olivo, M. S.
    Itri, L. M.
    Rugo, H. S.
    NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (16): : 1529 - 1541
  • [8] Sacituzumab govitecan: a new opportunity in the treatment of refractory metastatic triple-negative breast cancer
    Maltoni, Roberta
    Bravaccini, Sara
    ANNALS OF TRANSLATIONAL MEDICINE, 2022, 10 (07)
  • [9] Tackling metastatic triple-negative breast cancer with sacituzumab govitecan
    Schreiber, Anna R.
    Andress, Michelle
    Diamond, Jennifer R.
    EXPERT REVIEW OF ANTICANCER THERAPY, 2021, 21 (12) : 1303 - 1311
  • [10] Sacituzumab Govitecan-Hziy as treatment in metastatic breast cancer: a systematic review and meta-analysis of RCTs
    Liem, J. Andrina
    Wijovi, F.
    Herijanto, B. E.
    Gracia, J. L.
    Rustiadi, N. D. D.
    Julian, L.
    Sucahyo, E. C. K.
    Argo, T. M.
    Glory, H.
    Sugianto, J. O.
    Jhoputri, C. F.
    Rubismo, K. Y.
    Wirawan, G. R.
    Kurniawan, A.
    Huang, I.
    ANNALS OF ONCOLOGY, 2024, 35 : S1358 - S1358
12345